Diagnosis of infectious diseases such as influenza is seeing a sea change due to technological innovations and development of next-generation molecular tests such as nuclear acid amplification tests (NAATs) and advanced immunoassays. The global rapid influenza diagnostic tests market size is expected to grow over 8% compound annual growth rate during the forecast period (2019–2029).
Conventional immunoassays tend to be limited by their sensitivity and specificity, a shortcoming expected to be overcome through product innovation by key molecular diagnostics companies. Quidel and BD have integrated electronic readers with immunoassays, to increase test sensitivity without switching to other expensive detection devices.
- In the last few years, constant increase in demand for rapid point-of-care tests has prompted healthcare providers to shift to rapid influenza diagnostic tests that can achieve results in 15 minutes or less.
- In terms of principle, immunochromatographic assays are expected to gain the maximum share in the rapid influenza diagnostic tests market, which is attributable to its low cost and easy-to-use nature.
- Attributable to growing number of clinics, hospitals and diagnostic centres, the global rapid influenza diagnostic tests market in North America is at the forefront and it is expected to remain the most profitable region during the forecast period.
- South Asia is anticipated to be the fastest-growing region due to the high prevalence of seasonal influenza and an increasing preference to opt for diagnostic testing.
